SPOTLIGHT -
Dr. Pinheiro on Determinants of Cost in the Treatment of T1-T3 Oropharynx Cancer
A. Daniel Pinheiro, MD, physician, Otolaryngology, Mercy Clinic, discusses a study looking at the determinants of cost in the treatment of patients with T1 to T3 oropharynx cancer.
Read More
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL